Nanobiotix S.A.
ENXTPANanobiotix heads into its May 22 results carrying a sharp contradiction: clinical data strong enough to impress oncologists, yet a stock that just shed 10% in a single session. The immediate catalyst is a striking mismatch between headline and market reaction. Phase 2 data from the CONVERGE trial — evaluating JNJ-1900 (NBTXR3) with Johnson & Johnson in stage III inoperable…
Snapshot as of 20 May 2026
Nanobiotix heads into its May 22 results carrying a sharp contradiction: clinical data strong enough to impress oncologists, yet a stock that just shed 10% in a single session. The immediate catalyst is a striking…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NANO — free to start on ORTEX.
Sign up for free →Open NANO on ORTEX